Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression

Clinical Pharmacokinetics

Volumn 39, Issue 6, 2000, Pages 413-427

  Fleishaker, J C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; FLUOXETINE; KETOCONAZOLE; LORAZEPAM; NORADRENALIN UPTAKE INHIBITOR; QUINIDINE; REBOXETINE;

AREA UNDER THE CURVE; CHIRALITY; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENANTIOMER; FOOD DRUG INTERACTION; HUMAN; KIDNEY DISEASE; LIVER DYSFUNCTION; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY;

EID: 0034491028     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039060-00003     Document Type: Review

References (39)

1. Potential antidepressant agents: α-aryloxy-benzyl derivatives of ethanolamine and morpholine
2. The role of norepinephrine in the treatment of depression
3. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: Behavioural and biochemical studies
4. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder
5. Reboxetine: A double-blind comparison with fluoxetine in major depressive disorder
6. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor
7. Differential pharmacology of the newer antidepressants
8. Metabolism of the newer antidepressants: An overview of the pharmacological and pharmacokinetic implications
9. Stereoselecfive and species-dependent kinetics of reboxetine in mouse and rat
10. Hemodynamic effects of reboxetine in healthy male volunteers
11. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics
12. Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding
13. Pharmacokinetics of reboxetine in healthy volunteers: Relative bioavailability and food effect
14. Pharmacokinetics of reboxetine in healthy volunteers of different ages
15. Pharmacokinetics of reboxetine in the elderly: Advances in simultaneous pharmacokinetic/pharmacodynamic modeling
16. Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency
17. Pharmacokinetics of reboxetine in volunteers with hepatic impairment
18. Effect of lorazepam on the pharmacokinetics of reboxetine in healthy volunteers
19. Genetic polymorphism and reboxetine metabolism
20. Dose proportionality of reboxetine enantiomers in healthy volunteers
21. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans
22. Pharmacokinetics of reboxetine in healthy volunteers: Single against repeated oral doses and lack of enzymatic alterations
23. Lack of effect of reboxetine on electrocardiographic parameters in healthy volunteers
24. Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man
25. Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers
26. Cytochrome P450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes
27. Pharmacokinetics of reboxetine enantiomers in healthy volunteers
28. Pharmacokinetics of reboxetine in elderly patients with depressive disorders
29. Chronic renal failure (CRF) affects the disposition of hepatically metabolized drugs
30. Alprazolam in end-stage renal disease: 1. Pharmacokinetics
31. Inhibitory potential of reboxetine on major drug metabolizing forms of P450 in humans
32. Effect of reboxetine on the pharmacokinetics of lorazepam in healthy volunteers
33. Combined MAOI-tricyclic antidepressant treatment: A reevaluation
34. Adverse consequences of fluoxetine-MAOi combination therapy
35. The serotonin syndrome
36. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: In vitro and in vivo studies
37. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers
38. The effects of reboxetine and nefazodone on the pharmacokinetics and pharmacodynamics of alprazolam